Overall, these in vivo experimental findings suggest that loss of SMARCB1 increased BLCA tumor growth and metastasis, consistent with the clinical association of low SMARCB1 BLCA tumors with worse outcomes. This evidence concerns the gene SMARCB1 and bladder transitional cell carcinoma.